Global Information
회사소개 | 문의 | 비교리스트

노안 : 파이프라인 리뷰

Presbyopia (Ophthalmology) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 12월 상품코드 410994
페이지 정보 영문 78 Pages 배송안내
가격
US $ 2,000 ₩ 2,574,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 5,149,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,723,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


노안 : 파이프라인 리뷰 Presbyopia (Ophthalmology) - Drugs in Development, 2021
발행일 : 2021년 12월 페이지 정보 : 영문 78 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

노안은 근처에 있는 대상물에 빠르게 초점을 맞추는 능력이 서서히 약화되는 눈의 상태입니다. 노안은 노화와 함께 일어납니다. 증후는 두통, 안정피로, 작은 글자를 읽기 어려움, 피로 등이 있습니다. 위험인자로서 빈혈, 당뇨병, 순환기계 질환, 원시, 다발성 경화증, 중증 근무력증, 안외상 등을 들 수 있습니다.

노안(Presbyopia) 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업과 연구기관에 의해서 개발중인 치료제, 치료제 평가, 후기 단계 등의 정보를 전해드립니다.

서론

  • 조사 범위

노안 개요

치료제 개발

  • 파이프라인 제품 : 개요

기업에서 개발중인 치료제

파이프라인 제품 개요

  • 임상 단계 제품
  • 초기 단계 제품

기업에서 개발중인 제품

치료제 개발에 참여하고 있는 기업

  • Allergan Plc
  • Encore Vision Inc
  • Orasis Pharmaceuticals Ltd
  • Presbyopia Therapies LLC
  • ViewPoint Therapeutics Inc

치료제 평가

  • 단독치료 제품별
  • 병용 제품별
  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

약제 개요

  • (aceclidine + tropicamide)
  • (oxymetazoline hydrochloride + pilocarpine hydrochloride)
  • EV-06
  • lanosterol
  • oxymetazoline hydrochloride
  • PresbiDrops
  • VP-1001

부록

도표

KSM 17.02.22

List of Tables

List of Tables

  • Number of Products under Development for Presbyopia, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Presbyopia - Pipeline by AbbVie Inc, 2021
  • Presbyopia - Pipeline by Cellix Bio Pvt Ltd, 2021
  • Presbyopia - Pipeline by Eyenovia Inc, 2021
  • Presbyopia - Pipeline by Glaukos Corp, 2021
  • Presbyopia - Pipeline by Intratus Inc, 2021
  • Presbyopia - Pipeline by Kedalion Therapeutics Inc, 2021
  • Presbyopia - Pipeline by Kubota Vision Inc, 2021
  • Presbyopia - Pipeline by Lenz Therapeutics LLC, 2021
  • Presbyopia - Pipeline by Novartis AG, 2021
  • Presbyopia - Pipeline by Ocuphire Pharma Inc, 2021
  • Presbyopia - Pipeline by Orasis Pharmaceuticals Ltd, 2021
  • Presbyopia - Pipeline by Plex Pharmaceuticals Inc, 2021
  • Presbyopia - Pipeline by Reven Holdings Inc, 2021
  • Presbyopia - Pipeline by Santen Pharmaceutical Co Ltd, 2021
  • Presbyopia - Pipeline by ViewPoint Therapeutics Inc, 2021
  • Presbyopia - Pipeline by Visus Therapeutics Inc, 2021
  • Presbyopia - Pipeline by Vyluma Inc, 2021
  • Presbyopia - Dormant Projects, 2021

List of Figures

List of Figures

  • Number of Products under Development for Presbyopia, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Presbyopia - Drugs In Development, 2021, provides an overview of the Presbyopia (Ophthalmology) pipeline landscape.

Presbyopia is an eye condition in which eye slowly loses the ability to focus quickly on objects that are close. Presbyopia happens in people as they age. Signs and symptoms include headaches, eyestrain, difficulty reading small print and fatigue. Risk factors include anemia, diabetes, cardiovascular disease, hyperopia, multiple sclerosis, myasthenia gravis and eye trauma.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Presbyopia - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Presbyopia (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Presbyopia (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Presbyopia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 9, 3, 4 and 2 respectively.

Presbyopia (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Presbyopia (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Presbyopia (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Presbyopia (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Presbyopia (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Presbyopia (Ophthalmology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Presbyopia (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Presbyopia (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Presbyopia - Overview
  • Presbyopia - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Presbyopia - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Presbyopia - Companies Involved in Therapeutics Development
  • Presbyopia - Drug Profiles
  • Presbyopia - Dormant Projects
  • Presbyopia - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q